For Our Patients
Clinical Trials and Research
Enrolling in
a Study
Thank you for your interest in enrolling in one of our studies.
New patients interested in participating in a clinical trial and in enrolling to possibly receive the newest, most advanced treatment for their vitreoretinal conditions, with the care and attention from our professional clinical trial staff.
Currently Enrolling Studies
New patients interested in enrolling a study, please click on the Enroll in this Study to send us an email. Include your name, the reason of your interest in this study and the office location you receive treatment. You will receive a reply from us within 48 - 72 hours.
The following studies are currently available for enrollment.
For Central Florida Patients
QUASAR - Retinal Vein Occlusions
Title: Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macula Edema due to Retinal Vein Occlusion (RVO)
For Referring Doctors
Treatment-naive macular edema involving foveal center secondary to RVO (BRVO, HRVO,CRVO) diagnosed within 16 weeks (112 days) before the screening visit in the study eye
BCVA OF 20/40 to 20/320
Decrease in BCVA determined to be primarily the result of RVO in the study eye.
Mean CST value on OCT greater than or equal to 320 µm if including Bruch's membrane
must be pseudophakic in the study eye
HbA1c 12% or less
Age: Adult of > 18 years of age
ASCENT - Wet Macular Degeneration
Title: A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD
For Referring Doctors
Diagnosis of CNV secondary to AMD in the study eye (diagnosed < 4 years from screening visit)
CNV with fluid within 3mm center of macula
BCVA: 20/25-20/160 (inclusive)
Age: 50-89 (inclusive)
NOT Treatment Naive - Study Eye must have less than 12 anti-VEGF in the 12 months prior to screening visit
must be pseudophakic in the study eye for at least 12 weeks
ELEVATUM - Diabetic Macular Edema
Title: A Phase IIIB/IV, Multicenter, Open-Label, Single-Arm Study To Investigate Faricimab (RO6867461) Treatment Response In Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
For Referring Doctors
Patients who self-identify as Black/African American, Hispanic/Latino American, or Native American/Alaska Native/Native Hawaiian or other Pacific Islander
Age of 18 years or older
Diagnosis of diabetes mellitus (type 1 or type 2)
HbA1c of 10% or less
Treatment Naive - have not received previous treatment with any anti-VEGF IVT or corticosteroids
DME defined as macular thickening involving the center of the macula with a CST value greater than 325 µm
BCVA 20/40-20/320
women of child-bearing age must agree to the usage of contraception or remain abstinent
must be pseudophakic in the study eye
SHANGHAI HENLIUS for Wet Age-Related Macular Degeneration
Title: A Phase 3, Randomized, Double-masked, Active Controlled Study to Compare the Efficacy and Safety of HLX04-O Administered by Intravitreal Injection with Ranibizumab in Subjects with wet Age-related Macular Degeneration (wAMD)
For Referring Doctors
Newly diagnosed wAMD in the study eye
Must be treatment-naive
Study Eye BCVA: 20/40-20/320
Fellow Eye BCVA: 20/320 or better
Age 50 years or older
IRF OR SRF on OCT and leakage on FA
HbA1c 10% or less
Magic ML43601 (SSU00210735)
Title: FARICIMAB FOR RETINAL NON-PERFUSION ASSOCIATED WITH NON-PROLIFERATIVE DIABETIC RETINOPATHY: THE MAGIC PHASE 2, MULTI-CENTER, OPEN-LABEL, RANDOMIZED CONTROLLED TRIAL
Active Studies but Closed for Enrollment
New Day is for Diabetic Macula EDEMA
A Randomized, Masked, Controlled Study of and Intravitreal ILUVIEN implant as baseline therapy in patients with Early Diabetic Macular Edema.
Pulsar WET MACULAR DEGENERATION
Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
For North Florida Patients
Boehringer Ingelheim BI 771716 – Dry Macular Degeneration
BI 771716 is a single chain variable fragment (scFv) with high affinity to human C3 and C3b with the potential to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
F. Hoffmann-La Roche Ltd-RIVOL1-CRVO
A PHASE Ib, MULTICENTER, RANDOMIZED, DOUBLE MASKED, ACTIVE COMPARATORCONTROLLED STUDY TO INVESTIGATE THE BIOLOGICAL ACTIVITY, SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7200394 IN PARTICIPANTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION
DRCR-Protocol AF- Non-Proliferative Diabetic Retinopathy
A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening.
DRCR-Protocol AO- Home OCT vs Treat and Extend Study
Home OCT-Guided Treatment versus Treat and Extend for the Management of Neovascular AMD (Protocol AO)
Active Studies but Closed for Enrollment
SHANGHAI HENLIUS FOR WET AMD
DRCR- Protocol AM- Epiretinal Membranes
Genentech, Inc – Magic ML43601- NPDR
ONL Therapeutics, Inc. (Retinal Detachment)
DRCR-Protocol AJ- Macula Hole
Vitreous Proteomics in Eyes with a Macular Hole.
For more information about clinical trials or if you should have any questions, please feel free to contact us.
